These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 5980274)

  • 21. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Moxonidine. A new antihypertensive agent of central action].
    Leães CG; Rosito GA
    Arq Bras Cardiol; 1998 Jun; 70(6):443-8. PubMed ID: 9713089
    [No Abstract]   [Full Text] [Related]  

  • 23. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Catapresan. A new antihypertensive drug].
    Naess K; Lund-Larsen PG
    Tidsskr Nor Laegeforen; 1970 Feb; 90(4):416-9. PubMed ID: 5426474
    [No Abstract]   [Full Text] [Related]  

  • 25. Losartan--a new antihypertensive.
    Drug Ther Bull; 1995 Oct; 33(10):73-4. PubMed ID: 7493558
    [No Abstract]   [Full Text] [Related]  

  • 26. [Moxonidin in heart failure: new therapeutic principles suppress neurohumoral activation. Supplement to the Congress on "Heart Failure" of the working group on cardiac insufficiency at the European Society for Cardiology. Cologne, May 1997].
    Dtsch Med Wochenschr; 1997 Sep; 122(36 Suppl Moxonidin):1-4. PubMed ID: 9330578
    [No Abstract]   [Full Text] [Related]  

  • 27. [Clonidine in migraine therapy].
    Tedeschi G
    Acta Neurol (Napoli); 1971; 26(5):633-42. PubMed ID: 5164729
    [No Abstract]   [Full Text] [Related]  

  • 28. Abrupt withdrawal of the antihypertensive agent tiamenidine after 12-months' treatment.
    Gerlis LS; Wright N
    Pharmatherapeutica; 1980; 2(6):408-11. PubMed ID: 7001495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of moxonidine in mild to moderate hypertension.
    Jain S; Malhotra P; Kumari S; Varma S
    J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heart and kidney involvement during antihypertensive treatment. Results from the primary preventive trial in Göteborg, Sweden.
    Samuelsson O; Wikstrand J; Wilhelmsen L; Berglund G
    Acta Med Scand; 1984; 215(4):305-11. PubMed ID: 6233842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Monitoring anti-arrhythmic therapy with dynamic ECG and serum levels].
    Meoli P; Sanna GP; Cataldo G; Massa D; Brusoni B
    Boll Soc Ital Cardiol; 1980; 25(9):1081-3. PubMed ID: 7284197
    [No Abstract]   [Full Text] [Related]  

  • 32. [The first clinical experience in Italy with angiotensin II receptor antagonists: results of a multicenter study on the efficacy and tolerance in arterial hypertension].
    Trimarco B
    Cardiologia; 1995 Dec; 40(12 Suppl 1):193-5. PubMed ID: 8998714
    [No Abstract]   [Full Text] [Related]  

  • 33. New angiotensin-II blocker.
    Lilley LL; Guanci R
    Am J Nurs; 1996 Mar; 96(3):20. PubMed ID: 8607540
    [No Abstract]   [Full Text] [Related]  

  • 34. [Long-term antihypertensive therapy with moxonidine (cynt) in patients with insulin-independent diabetes mellitus].
    Lazebnik LB; Malichenko SB; Serebrov AN
    Ter Arkh; 1997; 69(6):59-64. PubMed ID: 9297279
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical experimentation with Hypnofon. Apropos of 30 cases].
    Warembourg H; Jaillard J
    Lille Med; 1967 May; 12(4):Suppl:506-9. PubMed ID: 5307318
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical and experimental study with the new blood pressure depressant 2-(2,6-dichlorphenylamino)-2-imidazole-hydrochloride].
    Grabner G; Michalek P; Pokorny D; Vormittag E
    Arzneimittelforschung; 1966 Sep; 16(9):1174-9. PubMed ID: 6014738
    [No Abstract]   [Full Text] [Related]  

  • 37. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aliskiren and its rapidly, evolving role in the management of cardio-thoracic diseases.
    Kapoor S
    Heart Lung Circ; 2009 Oct; 18(5):372. PubMed ID: 19084475
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.